GLP-1 Medications May Not Increase Hypothyroidism Risk Compared to DPP-4 Inhibitors
A real-world cohort study from Saudi Arabia found no increased risk of hypothyroidism with GLP-1 receptor agonists compared to DPP-4 inhibitors.
Quick Facts
What This Study Found
GLP-1 receptor agonist use was not associated with increased hypothyroidism incidence compared to DPP-4 inhibitor use in Saudi Arabian adults.
Key Numbers
How They Did This
Active-comparator, new-user cohort study using the Saudi Real-World Evidence Research Network (SRWEN) from 2016-2023.
Why This Research Matters
Preclinical thyroid safety signals had raised concerns about GLP-1 RAs. Real-world evidence showing no increased hypothyroidism risk helps reassure patients and clinicians.
The Bigger Picture
As GLP-1 RA prescriptions surge globally, ongoing pharmacovigilance through real-world evidence studies like this is essential to confirm that preclinical safety signals don't translate to clinical risk.
What This Study Doesn't Tell Us
Observational design cannot prove causation; Saudi Arabian population may not be generalizable to all populations; follow-up duration may miss very late-onset effects.
Questions This Raises
- ?Do longer follow-up periods reveal different thyroid outcomes?
- ?Are specific GLP-1 RAs associated with different thyroid safety profiles?
Trust & Context
- Key Stat:
- No increased risk Hypothyroidism incidence similar between GLP-1 RA and DPP-4 inhibitor users
- Evidence Grade:
- Active-comparator cohort study — strong observational design with new-user approach, but still subject to unmeasured confounding.
- Study Age:
- Published 2026. Data from 2016-2023 covers the period of rapid GLP-1 RA adoption.
- Original Title:
- The Risk of Hypothyroidism With the Use of GLP-1 Receptor Agonists in Saudi Arabia.
- Published In:
- Pharmacoepidemiology and drug safety, 35(1), e70315 (2026)
- Authors:
- Alfakhri, Almaha, Almadani, Ohoud, Alroba, Raseel, Alrwisan, Adel, Alshaya, Omar, Albogami, Yasser
- Database ID:
- RPEP-14740
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs cause thyroid problems?
Animal studies raised concerns, but this large real-world study found no increased risk of hypothyroidism in people taking GLP-1 medications compared to those taking similar diabetes drugs.
Should I get my thyroid checked while on a GLP-1 medication?
Based on current evidence, routine thyroid monitoring beyond standard care is not specifically recommended for GLP-1 RA users, but discuss any concerns with your doctor.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14740APA
Alfakhri, Almaha; Almadani, Ohoud; Alroba, Raseel; Alrwisan, Adel; Alshaya, Omar; Albogami, Yasser. (2026). The Risk of Hypothyroidism With the Use of GLP-1 Receptor Agonists in Saudi Arabia.. Pharmacoepidemiology and drug safety, 35(1), e70315. https://doi.org/10.1002/pds.70315
MLA
Alfakhri, Almaha, et al. "The Risk of Hypothyroidism With the Use of GLP-1 Receptor Agonists in Saudi Arabia.." Pharmacoepidemiology and drug safety, 2026. https://doi.org/10.1002/pds.70315
RethinkPeptides
RethinkPeptides Research Database. "The Risk of Hypothyroidism With the Use of GLP-1 Receptor Ag..." RPEP-14740. Retrieved from https://rethinkpeptides.com/research/alfakhri-2026-the-risk-of-hypothyroidism
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.